DiaSorin S.p.A. (OTCMKTS:DSRLF) Given Average Recommendation of “Hold” by Brokerages

DiaSorin S.p.A. (OTCMKTS:DSRLF) has been assigned an average recommendation of “Hold” from the seven research firms that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating on the company.

A number of brokerages have recently issued reports on DSRLF. Zacks Research raised shares of DiaSorin to a “hold” rating in a research note on Tuesday, May 12th. UBS Group downgraded shares of DiaSorin from a “buy” rating to a “neutral” rating in a research note on Thursday, April 9th. Deutsche Bank Aktiengesellschaft lowered shares of DiaSorin from a “hold” rating to a “sell” rating in a report on Wednesday, June 17th. Piper Sandler started coverage on shares of DiaSorin in a research note on Thursday, June 11th. They issued a “neutral” rating on the stock. Finally, BNP Paribas Exane lowered shares of DiaSorin from a “neutral” rating to an “underperform” rating in a research report on Tuesday.

DiaSorin Stock Performance

DSRLF opened at $81.00 on Friday. The business has a fifty day moving average of $74.34 and a 200 day moving average of $76.13. DiaSorin has a 52-week low of $66.50 and a 52-week high of $100.00.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.